Dechra Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2023 was £1,569.4 Mil.
During the past 12 months, Dechra Pharmaceuticals's average Total Assets Growth Rate was 27.50% per year.
During the past 3 years, the average Total Assets Growth Rate was 14.00% per year.
During the past 5 years, the average Total Assets Growth Rate was 9.00% per year.
During the past 10 years, the average Total Assets Growth Rate was 18.80% per year.
During the past 13 years, Dechra Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 56.00%. The lowest was -12.80%. And the median was 14.00%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Dechra Pharmaceuticals's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dechra Pharmaceuticals (LSE:DPH) Total Assets Explanation
Note:
The Net Income data used here is two times the semi-annual (Jun. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Dechra Pharmaceuticals's Asset Turnover for the quarter that ended in Jun. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Dechra Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Dechra Pharmaceuticals (LSE:DPH) Business Description
Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:DPH has been successfully added to your 